Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F: all 28 studies that test it

Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTRecruitingNCT07764978Phase 3
• A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).RecruitingNCT07735637Phase 3
• A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingNCT07391657Phase 3
• CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant ParticipantsRecruitingNCT07350837Early Phase 1
• This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple SclerosisRecruitingNCT07303790Early Phase 1
• A Study of AZD0120 in Autoimmune DiseasesRecruitingNCT07295847Phase 1
• Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisRecruitingNCT07250269Phase 1
• An Open-label Study of AZD0120 in Adults With Multiple SclerosisRecruitingNCT07224373Phase 1
• GC012F Injection in Refractory Idiopathic Inflammatory MyopathyRecruitingNCT07086404Early Phase 1
• A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.RecruitingNCT07081646Phase 1/2
• A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)RecruitingNCT07073547Phase 1
• GC012F in Patients With Autoimmune DiseasesNot yet recruitingNCT07072884Early Phase 1
• GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)RecruitingNCT07058298Early Phase 1
• A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLERecruitingNCT06897930Phase 1/2
• An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia GravisNot yet recruitingNCT06759948Phase 1
• A Study of GC012F in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT06235229Phase 1/2
• Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) PatientsRecruitingNCT05858684Early Phase 1
• AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)RecruitingNCT05850234Phase 1/2
• Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus ErythematosusRecruitingNCT05846347Phase 1
• Study of FasT CAR-T GC012F Injection NDMM PatientsRecruitingNCT05840107Early Phase 1
• This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple SclerosisWithdrawnNCT07364487Early Phase 1
• An Open-label Study of GC012F in Rheumatoid Arthritis.WithdrawnNCT07315503Early Phase 1
• A Study of GC012F Injection in Subjects With Refractory Systemic Lupus ErythematosusActive, not recruitingNCT06530849Phase 1/2
• An Exploratory Clinical Study of GC012F Injection for Refractory gMGWithdrawnNCT06419166Early Phase 1
• Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple MyelomaStatus unknownNCT05412329Phase 1
• Study of FasT CAR-T GC012F Injection in High Risk TE NDMM PatientsStatus unknownNCT04935580Phase 1/2
• BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple MyelomaStatus unknownNCT04617704Early Phase 1
• BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple MyelomaStatus unknownNCT04236011Early Phase 1

← Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F overview